China (Mainland)
GLYX-13 CAS NO.117928-94-6
- Min.Order: 0 Metric Ton
- Payment Terms:
- Product Details
Keywords
- GLYX 13
- GLYX -13 enhance memory and learning
- NOOTROPICS
Quick Details
- ProName: GLYX-13
- CasNo: 117928-94-6
- Molecular Formula: C18H31N5O6
- Application: GLYX -13 enhance memory and learning
- ProductionCapacity: Metric Ton/Day
- Purity: 98%
- LimitNum: 0 Metric Ton
Superiority
| 77472-70-9 | phenylpiracetam | |
| 110958-19-5 | Fasoracetam | |
| 15180-02-6 | Amfonelic acid | |
| 68497-62-1 | Pramiracetam | |
| 116041-13-5 | Nebracetam | |
| 77191-36-7 | Nefiracetam | |
| 62613-82-5 | Oxiracetam | |
| 72432-10-1 | aniracetam | |
| 157115-85-0 | Noopept | |
| 59776-89-5 | Piracetam hydrazide | |
| 51352-87-5 | PRL-8-53 | |
| 22503-72-6 | IDRA-21 | |
| 1270138-40-3 | NSI-189 | |
| 272786-64-8 | Unifiram | |
| 314728-85-3 | Sunifiram | |
| 63547-13-7 | Adrafinil | |
| 33818-15-4 | Citicoline Sodium | |
| 987-78-0 | Citicoline | |
| 28319-77-9 | Alpha-GPC | |
| 120786-18-7 | Huperzine A | |
| 42971-09-5 | Vinpocetine | |
| 34271-54-0 | L-theanine | |
| 38183-03-8 | 7, 8 dihydroxy flavonoids | |
| 1689-64-1 | 9-fluorenol | |
| 127464-43-1 |
Mexidol |
Details
GLYX-13 is a selective, weak partial agonist of the glycine site of the NMDA receptor (IA ≈ 25%).[1] It has been shown to enhance memory and learning in both young adult and learning-impaired, aging rat models.[2] GLYX-13, a tetrapeptide (H-Thr-Pro-Pro-Thr-NH2), readily crosses the blood brain barrier, and has been shown to increase Schaffer collateral-CA1 long-term potentiation in vitro. In concert with a learning task it has also been shown to elevate gene expression of hippocampalNR1, a subunit of the NMDA receptor, in 3-month-old rats.[3] Neuroprotective effects have also been demonstrated inMongolian Gerbils by delaying the death of CA1, CA3, and dentate gyrus pyramidal neurons under glucose and oxygen-deprived conditions.[4]
Additionally, GLYX-13 has demonstrated antinociceptive activity, which is of particular interest, as both competitive and noncompetitive NMDA receptor antagonists are ataxic at analgesic doses, while GLYX-13 and other glycine subunit ligandsare able to elicit analgesia at sub-ataxic doses.[5]
